Insulin Implants Prevent the Temporal Development of Mechanical Allodynia and Opioid Hyposensitivity for 24-Wks in Streptozotocin (STZ)-Diabetic Wistar Rats

Pain Medicine

Volumn 12, Issue 5, 2011, Pages 782-793

  Otto, Kathleen J ^a   Wyse, Bruce D ^a,b   Cabot, Peter J ^a   Smith, Maree T ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Ctr for Drug Design and Development   (Australia)

Author keywords

Insulin Implants; Mechanical Allodynia; Morphine Hyposensitivity; Painful Diabetic Neuropathy; Streptozotocin (STZ) Diabetes in Rats

Indexed keywords

BENPEN; INSULIN; ISOFLURANE; MORPHINE; UNCLASSIFIED DRUG;

ADULT; ALLODYNIA; ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOALGESIA; IMPLANT; LONG TERM CARE; LONGITUDINAL STUDY; MALE; NONHUMAN; RAT; STREPTOZOCIN DIABETES; WISTAR RAT;

EID: 79955909691     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2011.01102.x     Document Type: Article

References (89)

1. Harzallah F, Ncibi N, Alberti H, etal. Clinical and metabolic characteristics of newly diagnosed diabetes patients: Experience of a university hospital in Tunis. Diabetes Metab 2006;32:632-5.
2. Geffken G, Williams L, Silverstein J, etal. Metabolic control and nocturnal enuresis in children with Type 1 diabetes. J Pediatr Nurs 2007;22:4-8.
3. Ryan M, Gallanagh J, Livingstone M, Gaillard C, Ritz P. The prevalence of abnormal eating behaviour in a representative sample of the French diabetic population. Diabetes Metab 2008;34:581-6.
4. Shera A, Miyan Z, Basit A, etal. Trends of type 1 diabetes in Karachi, Pakistan. Pediatr Diabetes 2008;9:401-6.
5. Roche E, Menon A, Gill D, Hoey H. Clinical presentation of type 1 diabetes. Pediatr Diabetes 2005;6:75-8.
6. Sugimoto K, Murakawa Y, Sima A. Diabetic neuropathy-A continuing enigma. Diabetes Metab Res Rev 2000;16:408-33.
7. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
8. Duby J, Campbell R, Setter S, White J, Rasmussen K. Diabetic neuropathy: An intensive review. Am J Health Syst Pharm 2004;61:160-76.
9. Gorson K, Ropper A. Additional causes for distal sensory polyneuropathy in diabetic patients. J Neurol Neurosurg Psychiatry 2006;77:354-8.
10. Arnér S, Meyerson B. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988;33:11-23.
11. Attal N, Chen Y, Kayser V, Guilbaud G. Behavioural evidence that systemic morphine may modulate a phasic pain-related behaviour in a rat model of peripheral mononeuropathy. Pain 1991;47:65-70.
12. Attal N. Chronic neuropathic pain: Mechanisms and treatment. Clin J Pain 2000;16:S118-30.
13. Bannon A, Decker M, Kim D, Campbell J, Arneric S. ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain. Brain Res 1998;801:158-63.
14. Courteix C, Bourget P, Caussade F, etal. Is the reduced efficacy of morphine in diabetic rats caused by alterations of opiate receptors or of morphine pharmacokinetics? J Pharmacol Exp Ther 1998;285:63-70.
15. Idanpaan-Heikkila J, Guilbaud G. Pharmacological studies on a rat model of trigeminal neuropathic pain: Baclofen, but not carbamazepine, morphine or tricyclic antidepressants, attenuates the allodynia-like behaviour. Pain 1999;79:281-90.
16. Chen S, Sweigart K, Lakoski J, Pan H. Functional μ opioid receptors are reduced in the spinal cord dorsal horn of diabetic rats. Anesthesiology 2002;97:1602-8.
17. Kamei J, Ohashi Y, Aoki R, Kawasima N, Kasuya Y. Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by μ-opioid agonists, but not by δ- and κ-opioid agonists. Brain Res 1992;571:199-203.
18. 2 opioid receptors. Neurosci Lett 1994;165:141-3.
19. Zurek J, Nadeson R, Goodchild C. Spinal and supraspinal components of opioid antinociception in streptozotocin induced diabetic neuropathy in rats. Pain 2001;90:57-63.
20. 2+ channels in attenuated morphine antinociception in streptozotocin-diabetic rats. Eur J Pharmacol 2002;435:187-94.
21. Singal A, Anjaneyulu M, Chopra K. Modulatory role of green tea extract on antinociceptive effect of morphine in diabetic mice. J Med Food 2005;8:386-91.
22. Ibironke G, Saba O. Effect of hyperglycemia on the efficacy of morphine analgesia in rats. Afr J Med Med Sci 2006;35:443-5.
23. Nozaki C, Saitoh A, Kamei J. Characterization of the antinociceptive effects of oxycodone in diabetic mice. Eur J Pharmacol 2006;535:145-51.
24. Gilhotra N, Sharma A, Singh M. Involvement of p38 MAPkinase in attenuation of antinociceptive effect of morphine in diabetic mice. Indian J Exp Biol 2007;45:654-6.
25. Leibovici M, Kanarek R. Diet selection improves morphine's antinociceptive actions in rats with streptozotocin-induced diabetes. Behav Neurosci 2007;121:965-75.
26. Torres-López J, Juárez-Rojop I, Granados-Soto V, etal. Peripheral participation of cholecystokinin in the morphine-induced peripheral antinociceptive effect in non-diabetic and diabetic rats. Neuropharmacology 2007;52:788-95.
27. Williams J, Haller V, Stevens D, Welch S. Decreased basal endogenous opioid levels in diabetic rodents: Effects on morphine and δ-9-tetrahydrocannabinoid-induced antinociception. Eur J Pharmacol 2008;584:78-86.
28. Gimbel J, Richards P, Portenoy R. Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology 2003;60:927-34.
29. Watson C, Moulin D, Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71-8.
30. Akimoto Y, Kreppel L, Hirano H, Hart G. Localization of the O-linked N-acetylglucosamine transferase in rat pancreas. Diabetes 1999;48:2407-13.
31. Hanover J, Lai Z, Le G, Lubas W, Sato S. Elevated O-linked N-acetylglucosamine metabolism in pancreatic β-cells. Arch Biochem Biophys 1999;367:51-60.
32. Konrad R, Mikolaenko I, Tolar J, Liu K, Kudlow J. The potential mechanism of the diabetogenic action of streptozotocin: Inhibition of pancreatic β-cell O-GlcNAc-selective N-acetyl-β-D-glucosaminidase. Biochem J 2001;356:31-41.
33. Elsner M, Guldbakke B, Tiedge M, Munday R, Lenzen S. Relative importance of transport and alkylation for pancreatic β-cell toxicity of streptozotocin. Diabetologia 2000;43:1528-33.
34. Tanaka Y, Shimizu H, Sato N, Mori M, Shimomura Y. Involvement of spontaneous nitric oxide production in the diabetogenic action of streptozotocin. Pharmacology 1995;50:69-73.
35. Szkudelski T. The mechanism of alloxan and streptozotocin action in β cells of the rat pancreas. Physiol Res 2001;50:536-46.
36. Mohamadin A, Hammad L, El-Bab M, Gawad H. Can nitric oxide-generating compounds improve the oxidative stress response in experimentally diabetic rats? Clin Exp Pharmacol Physiol 2007;34:586-93.
37. Yu J, Zhang Y, Yin X, etal. Protective effects of bendazac lysine on diabetic peripheral neuropathy in streptozotocin-induced diabetic rats. Clin Exp Pharmacol Physiol 2006;33:1231-8.
38. Courteix C, Eschalier A, Lavarenne J. Streptozotocin-induced diabetic rats: Behavioural evidence for a model of chronic pain. Pain 1993;53:81-8.
39. Ahlgren S, Levine J. Protein kinase C inhibitors decrease hyperalgesia and C-fibre hyperexcitability in the streptozotocin-diabetic rat. J Neurophysiol 1994;72:684-92.
40. Fox A, Eastwood C, Gentry C, Manning D, Urban L. Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. Pain 1999;81:307-16.
41. Dobretsov M, Hastings S, Romanovsky D, Stimers J, Zhang J. Mechanical hyperalgesia in rat models of systemic and local hyperglycemia. Brain Res 2003;960:174-83.
42. Courteix C, Privat A, Pelissier T, etal. Agmatine induces anti-hyperalgesic effects in diabetic rats and a superadditive interaction with D-CPP, a NMDA-receptor antagonist. J Pharmacol Exp Ther 2007;322:1237-45.
43. Drel V, Pacher P, Vareniuk I, etal. A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic mice. Eur J Pharmacol 2007;569:48-58.
44. 2+-dependent protein kinase C in the spinal cord to the development of mechanical allodynia in diabetic mice. Biol Pharm Bull 2007;30:990-3.
45. Hoybergs Y, Meert T. The effect of low-dose insulin on mechanical sensitivity and allodynia in type 1 diabetes neuropathy. Neurosci Lett 2007;417:149-54.
46. Obrosova I, Xu W, Lyzogubov V, etal. PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy. Free Radic Biol Med 2008;44:972-81.
47. Pabbidi R, Yu S, Peng S, etal. Influence of TRPV1 on diabetes-induced alterations in thermal pain sensitivity. Mol Pain 2008;4:9-26.
48. Sugimoto K, Rashid I, Shoji M, Suda T, Yasujima M. Early changes in insulin receptor signaling and pain sensation in streptozotocin-induced diabetic neuropathy in rats. J Pain 2008;9:237-45.
49. Nielsen C, Ross F, Lotfipour S, etal. Oxycodone and morphine have distinctly different pharmacological profiles: Radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 2007;132:289-300.
50. Otto K, Wyse B, Cabot P, Smith M. Longitudinal study of painful diabetic neuropathy in the zucker diabetic fatty rat model of type 2 diabetes: Impaired basal G-protein activity appears to underpin marked morphine hyposensitivity at six months. Pain Med Feb 18 2011. doi: 10.1111/j.1526-4637.2011.01067.x.
51. Peterson R, Shaw W, Neel M, Little L, Eichberg J. Zucker diabetic fatty rat as a model for non-insulin dependent diabetes mellitus. ILAR J 1990;32:16-9.
52. Leonard B, Watson R, Loomes K, Phillips A, Cooper G. Insulin resistance in the Zucker diabetic fatty rat: A metabolic characterisation of obese and lean phenotypes. Acta Diabetol 2005;42:162-70.
53. Lesniewski L, Donato A, Behnke B, etal. Decreased NO signaling leads to enhanced vasoconstrictor responsiveness in skeletal muscle arterioles of the ZDF rat prior to overt diabetes and hypertension. Am J Physiol 2008;294:H1840-50.
54. Watkins J, Klaunig J, Smith H, Cornwell P, Sanders R. Streptozotocin-induced diabetes increases γ-glutamyltranspeptidase activity but not expression in rat liver. J Biochem Mol Toxicol 1998;12:229-5.
55. Melin J, Hellberg O, Larsson E, Zezina L, Fellstrom B. Protective effect of insulin on ischemic renal injury in diabetes mellitus. Kidney Int 2002;61:1383-92.
56. Rastelli V, Akamine E, Oliveira M, etal. Influence of insulin on the microvascular response to inflammatory mediators in neonatal streptozotocin diabetic rats. Inflamm Res 2005;54:173-9.
57. Bi Y, Sun W, Chen X, etal. Effect of early insulin therapy on nuclear factor κB and cytokine gene expressions in the liver and skeletal muscle of high-fat diet, streptozotocin-treated diabetic rats. Acta Diabetol 2008;45:167-78.
58. Cunha J, Funez M, Cunha F, Parada C, Ferreira S. Streptozotocin-induced mechanical hypernociception is not dependent on hyperglycemia. Braz J Med Biol Res 2009;42:197-206.
59. Gireesh G, Kumar T, Mathew J, Paulose C. Enhanced muscarinic M1 receptor gene expression in the corpus striatum of streptozotocin-induced diabetic rats. J Biomed Sci 2009;16:38-49.
60. Qu X, Yang Y, Li J, Zeng Q, Gantz I. Agouti-related protein is a mediator of diabetic hyperphagia. Regul Pept 2001;98:69-75.
61. Ishii S, Kamegai J, Tamura H, etal. Role of ghrelin in streptozotocin-induced diabetic hyperphagia. Endocrinology 2002;143:4934-7.
62. Kuo D. Hypothalamic neuropeptide Y (NPY) and the attenuation of hyperphagia in streptozotocin diabetic rats treated with dopamine D1/D2 agonists. Br J Pharmacol 2006;148:640-7.
63. Han H, Park S. Alteration of the gene and protein levels of insulin-like growth factors in streptozotocin-induced diabetic male rats. J Vet Med Sci 2006;68:413-9.
64. Calcutt N, Jorge M, Yaksh Y, Chaplan S. Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: Effects of insulin, aldose reductase inhibition and lidocaine. Pain 1996;68:293-9.
65. Huang T, Price S, Chilton L, etal. Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. Diabetes 2003;52:2129-36.
66. Nasrallah R, Hébert R. Reduced IP receptors in STZ-induced diabetic rat kidneys and high-glucose-treated mesangial cells. Am J Physiol 2004;287:F673-81.
67. Chaplan S, Bach F, Pogrel J, Chung J, Yaksh T. Quantitative assessment of allodynia in the rat paw. J Neurosci Methods 1994;53:55-63.
68. Calcutt N, Chaplan S. Spinal pharmacology of tactile allodynia in diabetic rats. Br J Pharmacol 1997;122:1478-82.
69. Charles River Laboratories. Wistar rat. Animal Research Models. Available at: (accessed March 14, 2011).
70. Courteix C, Bardin M, Massol J, etal. Daily insulin treatment relieves long-term hyperalgesia in streptozotocin diabetic rats. Neuroreport 1996;7:1922-4.
71. Romanovsky D, Hastings S, Stimers J, Dobretsov M. Relevance of hyperglycemia to early mechanical hyperalgesia in streptozotocin-induced diabetes. JPNS 2004;9:62-9.
72. Romanovsky D, Cruz N, Dienel G, Dobretsov M. Mechanical hyperalgesia correlates with insulin deficiency in normoglycemic streptozotocin-treated rats. Neurobiol Dis 2006;24:384-94.
73. Piercy V, Banner S, Bhattacharyya A, etal. Thermal, but not mechanical, nociceptive behaviour is altered in the Zucker diabetic fatty rat and is independent of glycaemic status. J Diabetes Complications 1999;13:163-9.
74. Sugimoto K, Rashid I, Kojima K, etal. Time course of pain sensation in rat models of insulin resistance, type 2 diabetes, and exogenous hyperinsulinaemia. Diabetes Metab Res Rev 2008;24:642-50.
75. Adler A, Boyko E, Ahroni J, etal. Risk factors for diabetic peripheral neuropathy: Results of the Seattle Prospective Diabetic Foot Study. Diabetes Care 1997;20:1162-67.
76. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
77. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
78. Zhuang H, Snyder C, Pu S, Ishii D. Insulin-like growth factors reverse or arrest diabetic neuropathy: Effects on hyperalgesia and impaired nerve regeneration in rats. Exp Neurol 1996;140:198-205.
79. Zhuang H, Wuarin L, Fei Z, Ishii D. Insulin-like growth factor (IGF) gene expression is reduced in neural tissues and liver from rats with non-insulin-dependent diabetes mellitus, and IGF treatment ameliorates diabetic neuropathy. J Pharmacol Exp Ther 1997;283:366-74.
80. Chu Q, Moreland R, Yew N, etal. Systemic insulin-like growth factor-1 reverses hypoalgesia and improves mobility in a mouse model of diabetic peripheral neuropathy. Mol Ther 2008;16:1400-8.
81. 5]-enkephalin in normal and diabetic rats. Anesthesiology 2003;98:217-22.
82. Hall K, Liu J, Sima A, Wiley J. Impaired inhibitory G-protein function contributes to increased calcium currents in rats with diabetic neuropathy. J Neurophysiol 2001;86:760-70.
83. Lee J, Hahm E, Min B, Cho Y. Activation of protein kinase C antagonizes the opioid inhibition of calcium current in rat spinal dorsal horn neurons. Brain Res 2004;1017:108-19.
84. Narita M, Ohsawa M, Mizoguchi H, Kamei J, Tseng L. Pretreatment with protein kinase C activator phorbol 12, 13-dibutyrate attenuates the antinociception induced by μ- but not ε-opioid receptor agonist in the mouse. Neuroscience 1996;76:291-8.
85. 5]enkephalin-induced antinociception in diabetic mice. Eur J Pharmacol 1997;339:27-31.
86. Mao J. NMDA and opioid receptors: Their interactions in antinociception, tolerance and neuroplasticity. Brain Res Rev 1999;30:289-304.
87. Huang L, Edwards S, Smith M. Comparison of the pharmacokinetics of oxycodone and noroxycodone in male Dark Agouti and Sprague-Dawley rats: Influence of streptozotocin-induced diabetes. Pharm Res 2005;22:1489-98.
88. Ohsawa M, Kamei J. Modification of κ-opioid receptor agonist-induced antinociception by diabetes in the mouse brain and spinal cord. J Pharmacol Sci 2005;98:25-32.
89. Ross F, Smith M. The intrinsic antinociceptive effects of oxycodone appear to be κ-opioid receptor mediated. Pain 1997;73:151-7.